Understanding how side effects relate to each dose level helps you know what to expect at each stage
Gastric inhibitory polypeptide (GIP) binding sites in rat brain
doi: 10.1007/s40259-013-0057-y 127 McCartyDColemanMBolandCL
If the question is "what does the science suggest is coming," retatrutide's phase 2 weight-loss and liver-fat numbers are genuinely notable but "promising in phase 2" and "proven and approved" are very different standards, and the gap between them is exactly what phase 3 exists to test
At the same time, there are potential downsides with these medications, such as high cost, side effects, and questions about long-term use
This is accelerating adoption across hospitals, specialty obesity clinics, and endocrinology practices, thereby driving market growth